

Mindray (300760 CH)

Robust performance in a challenging industry environment

Mindray achieved a revenue of RMB20.5bn in 1H24, marking an 11.1% increase YoY, and reported an attributable net profit of RMB7.6bn, up 17.4% YoY. Despite the ongoing regulatory adjustments in the healthcare industry and the delay in medical equipment renewals projects, which have led to a cautious approach towards bidding and procurement activities in public hospitals, the revenue from domestic equipment business decreased by 12% YoY. However, thanks to the rapid growth of the IVD business and the domestic high-end/ultra-high-end ultrasound business, Mindray still demonstrated strong resilience and steady growth. The increase in the revenue share from IVD reagents and high-end ultrasounds drove the Company's gross margin up by 0.7 ppt YoY to 66.3% in 1H24. Additionally, Mindray announced a mid-term dividend plan, distributing a total cash dividend of approximately RMB4.9bn, which represents a payout ratio of more than 65%, indicating an ongoing increase in the dividend payout.

- Domestic equipment business faces pressure.** In 1H24, the continued delay in bidding and procurement activities led to a 12% YoY decrease in revenue from domestic equipment business. Due to the high market share of Mindray's Patient Monitoring and Life Support (PMLS) products in China, the domestic business was significantly affected by the industry environment, with the PMLS segment experiencing a 7.6% YoY decrease in revenue, including about a 20% drop in domestic revenue. The Medical Imaging segment benefited from the volume increase of the first domestic ultra-high-end ultrasound Resona A20 and other high-end ultrasounds, resulting in a 15.5% YoY revenue growth in this segment, with high-end and ultra-high-end ultrasound revenues increasing by over 40%.
- Accelerating the shift towards consumables-related business.** In 1H24, the IVD reagent business was minimally affected by domestic industry regulation, with revenue increasing by 28% YoY to RMB7.7bn, accounting for over 37% of total revenue. Domestic IVD revenue grew by over 25%, and domestic reagent revenue increased by 30%, with reagent revenue representing over 80% of domestic IVD revenue. Internationally, Mindray successfully penetrated over 60 overseas third-party chain laboratories in 1H24 and installed the first MT 8000 TLA, driving a more than 30% YoY increase in overseas IVD revenue. We believe that the continuous increase in domestic diagnostic demand and the implementation of IVD VBP are expected to help Mindray rapidly expand its domestic market share, while accelerated cooperation with high-end clients will support long-term rapid growth of the IVD overseas market. Additionally, the minimally invasive surgery business grew by 90% YoY in 1H24. The Company's acquisition of APT Medical also filled the gap in its cardiovascular consumables business. Currently, consumables-related businesses led by IVD already account for over 50% of the Company's domestic revenue.
- Maintain BUY.** We believe that industry regulation has not affected the essential demand for hospital procurement. As industry regulation becomes normalized and equipment renewal policies are implemented, hospital **procurement is expected to gradually recover**. Based on a 9-year DCF model, we adjust the target price to RMB 352.84 (WACC: 10.3%, perpetual growth rate: 3.0%).

Earnings Summary

(YE 31 Dec)	FY22A	FY23A	FY24E	FY25E	FY26E
Revenue (RMB mn)	30,366	34,932	40,612	48,807	57,440
YoY growth (%)	20.2	15.0	16.3	20.2	17.7
Adjusted net profit (RMB mn)	9,525	11,434	13,643	16,229	19,054
YoY growth (%)	21.3	20.0	19.3	19.0	17.4
EPS (Adjusted) (RMB)	7.87	9.44	11.26	13.39	15.72
Adjusted P/E (x)	31.9	26.6	22.3	18.7	16.0
Net gearing (%)	(72.5)	(56.8)	(44.9)	(51.1)	(57.2)

Source: Company data, Bloomberg, CMBIGM estimates

BUY (Maintain)

Target Price RMB352.84

(Previous TP) RMB383.49)

Up/Downside 40.7%

Current Price RMB250.80

China Healthcare

Jill WU, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

Cathy WANG

(852) 3916 1729

cathywang@cmbi.com.hk

Stock Data

Mkt Cap (RMB mn)	303,453.2
Avg 3 mths t/o (RMB mn)	1,007.0
52w High/Low (RMB)	313.16/226.52
Total Issued Shares (mn)	1209.9

Source: FactSet

Shareholding Structure

Smartco Development Limited	27.0%
Magnifice (HK) Limited	24.5%


Source: HKEx

Share Performance

	Absolute	Relative
1-mth	1.1%	2.5%
3-mth	-16.0%	-9.1%
6-mth	-13.3%	-8.2%

Source: FactSet

12-mth Price Performance



Source: FactSet

Figure 1: Earnings revision

RMB mn	New			Old			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	40,612	48,807	57,440	41,996	49,635	57,739	-3.29%	-1.67%	-0.52%
Gross profit	27,011	32,632	38,522	28,025	33,291	38,883	-3.62%	-1.98%	-0.93%
Operating profit	15,928	19,150	22,578	15,948	19,125	22,572	-0.13%	0.13%	0.03%
Net profit	13,727	16,313	19,137	13,905	16,481	19,357	-1.27%	-1.02%	-1.13%
EPS (RMB)	11.32	13.45	15.78	11.47	13.59	15.97	-1.27%	-1.02%	-1.13%
Gross margin	66.51%	66.86%	67.06%	66.73%	67.07%	67.34%	-0.23ppt	-0.21ppt	-0.28ppt
Operating margin	39.22%	39.24%	39.31%	37.98%	38.53%	39.09%	+1.24ppt	+0.71ppt	+0.21ppt
Net margin	33.80%	33.42%	33.32%	33.11%	33.20%	33.52%	+0.69ppt	+0.22ppt	-0.21ppt

Source: Company data, Bloomberg, CMBIGM estimates

Figure 2: Risk-adjusted DCF valuation

DCF Valuation (in RMB mn)	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E
EBIT	15,520	18,708	22,020	25,741	30,042	35,069	40,885	47,557	55,097
Tax rate	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%	11.00%
EBIT*(1-tax rate)	13,813	16,650	19,598	22,910	26,738	31,211	36,388	42,326	49,036
+ D&A	1,144	1,274	1,391	1,492	1,575	1,639	1,689	1,724	1,746
- Change in working capital	-617	-1,028	-1,087	-1,230	-1,425	-1,680	-1,945	-2,202	-2,481
- Capx	-7,936	-1,778	-1,778	-1,678	-1,578	-1,478	-1,378	-1,278	-1,178
FCFF	6,404	15,118	18,124	21,494	25,309	29,693	34,753	40,569	47,122
Terminal value									668,310

Terminal growth rate	3.0%
WACC	10.3%
Cost of Equity	13.5%
Cost of Debt	5.0%
Equity Beta	1.00
Risk Free Rate	3.0%
Market Risk Premium	10.5%
Target Debt to Asset ratio	35.0%
Effective Corporate Tax Rate	15.0%

Terminal value	277,413
Total PV	411,436
Net debt	-17,014
Minority	656
Equity value	427,793
# of shares (mn)	1,212
DCF per share (in RMB)	352.84

Source: CMBIGM estimates

Figure 3: Sensitivity analysis

		WACC				
		9.3%	9.8%	10.3%	10.8%	11.3%
Terminal growth rate	4.0%	475.94	430.22	391.95	359.47	331.58
	3.5%	444.39	404.66	370.95	342.00	316.90
	3.0%	417.88	382.88	352.84	326.79	304.00
	2.5%	395.29	364.10	337.06	313.41	292.57
	2.0%	375.81	347.74	323.19	301.56	282.38

Source: CMBIGM estimates

Figure 4: CMBIGM estimates vs consensus

RMB mn	CMBIGM			Consensus			Diff (%)		
	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E	FY24E	FY25E	FY26E
Revenue	40,612	48,807	57,440	41,677	49,745	59,091	-2.56%	-1.89%	-2.79%
Gross profit	27,011	32,632	38,522	27,560	32,947	39,169	-1.99%	-0.95%	-1.65%
Operating profit	15,928	19,150	22,578	15,477	18,559	22,117	2.91%	3.19%	2.08%
Net profit	13,727	16,313	19,137	13,888	16,638	19,892	-1.16%	-1.96%	-3.79%
EPS (RMB)	11.32	13.45	15.78	11.47	13.76	16.43	-1.30%	-2.19%	-3.94%
Gross margin	66.51%	66.86%	67.06%	66.13%	66.23%	66.29%	+0.38ppt	+0.63ppt	+0.78ppt
Operating margin	39.22%	39.24%	39.31%	37.14%	37.31%	37.43%	+2.08ppt	+1.93ppt	+1.88ppt
Net margin	33.80%	33.42%	33.32%	33.32%	33.45%	33.66%	+0.48ppt	-0.02ppt	-0.35ppt

Source: Company data, Bloomberg, CMBIGM estimates

Financial Summary

INCOME STATEMENT	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Revenue	25,270	30,366	34,932	40,612	48,807	57,440
Cost of goods sold	(8,843)	(10,885)	(11,821)	(13,601)	(16,175)	(18,918)
Gross profit	16,427	19,480	23,111	27,011	32,632	38,522
Operating expenses	(7,825)	(8,941)	(10,170)	(11,469)	(13,869)	(16,331)
Selling expense	(3,999)	(4,802)	(5,703)	(6,092)	(7,321)	(8,616)
Admin expense	(1,106)	(1,320)	(1,524)	(1,665)	(2,001)	(2,355)
R&D expense	(2,524)	(2,923)	(3,433)	(3,655)	(4,441)	(5,284)
Others	(196)	103	489	(58)	(105)	(75)
Operating profit	9,066	10,991	13,070	15,928	19,150	22,578
Gain/loss on financial assets at FVTPL	10	(21)	79	0	0	0
Investment gain/loss	1	(5)	(10)	0	0	0
Other gains/(losses)	453	478	60	387	387	387
Others	(49)	(37)	(59)	(59)	(59)	(59)
Pre-tax profit	9,017	10,954	13,011	15,869	19,091	22,519
Income tax	(1,013)	(1,343)	(1,433)	(1,746)	(2,100)	(2,477)
Minority interest	(2)	(4)	4	(396)	(679)	(905)
Net profit	8,004	9,611	11,578	14,123	16,991	20,042
Adjusted net profit	7,850	9,525	11,434	13,643	16,229	19,054
Gross dividends	4,252	5,456	7,032	8,923	10,685	12,631
BALANCE SHEET						
YE 31 Dec (RMB mn)						
Current assets	21,335	30,606	26,875	25,904	32,692	40,738
Cash & equivalents	15,361	23,186	18,787	17,023	22,241	28,623
Account receivables	1,790	2,661	3,297	3,463	4,162	4,898
Inventories	3,565	4,025	3,979	4,605	5,476	6,405
Prepayment	238	289	268	268	268	268
Other current assets	380	445	545	545	545	545
Non-current assets	16,768	16,139	21,065	27,412	27,472	27,416
PP&E	3,772	4,261	5,490	6,851	8,083	9,197
Deferred income tax	596	755	1,313	1,313	1,313	1,313
Intangibles	2,061	1,977	2,225	1,841	1,457	1,073
Goodwill	4,218	4,403	5,062	11,147	11,147	11,147
Other non-current assets	6,120	4,743	6,976	6,260	5,473	4,685
Total assets	38,103	46,745	47,940	53,316	60,164	68,154
Current liabilities	8,629	11,770	10,103	10,278	10,820	11,398
Short-term borrowings	0	0	8	8	8	8
Account payables	2,281	2,291	2,690	2,866	3,408	3,986
Tax payable	474	573	653	653	653	653
Other current liabilities	5,874	8,906	6,751	6,751	6,751	6,751
Non-current liabilities	2,506	2,976	4,491	4,491	4,491	4,491
Long-term borrowings	0	0	1	1	1	1
Deferred income	105	93	109	109	109	109
Other non-current liabilities	2,401	2,883	4,381	4,381	4,381	4,381
Total liabilities	11,135	14,746	14,594	14,769	15,312	15,889
Share capital	1,216	1,212	1,212	1,212	1,212	1,212
Capital surplus	608	608	608	608	608	608
Other reserves	25,129	30,161	31,265	36,070	41,698	48,204
Total shareholders equity	26,953	31,981	33,085	37,890	43,518	50,025
Minority interest	15	18	261	656	1,335	2,240
Total equity and liabilities	38,103	46,745	47,940	53,316	60,164	68,154

CASH FLOW	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec (RMB mn)						
Operating						
Profit before taxation	9,017	10,954	13,011	15,869	19,091	22,519
Depreciation & amortization	717	911	1,039	1,144	1,274	1,391
Tax paid	(1,013)	(1,343)	(1,433)	(1,746)	(2,100)	(2,477)
Change in working capital	328	1,524	(1,652)	(617)	(1,028)	(1,087)
Others	(50)	96	96	96	61	(55)
Net cash from operations	8,999	12,141	11,062	14,746	17,298	20,291
Investing						
Capital expenditure	(1,402)	(1,916)	(2,689)	(2,000)	(2,000)	(2,000)
Acquisition of subsidiaries/ investments	(3,520)	0	(871)	(6,157)	0	0
Net proceeds from disposal of short-term investments	0	0	0	200	200	200
Others	110	(1,304)	2,867	22	22	22
Net cash from investing	(4,812)	(3,220)	(693)	(7,936)	(1,778)	(1,778)
Financing						
Dividend paid	(3,039)	(4,233)	(10,670)	(8,574)	(10,302)	(12,131)
Net borrowings	(441)	0	(19)	0	0	0
Proceeds from share issues	0	0	79	0	0	0
Others	(1,125)	(961)	(166)	0	0	0
Net cash from financing	(4,605)	(5,194)	(10,776)	(8,574)	(10,302)	(12,131)
Net change in cash						
Cash at the beginning of the year	15,723	15,133	18,974	18,787	17,023	22,241
Exchange difference	(171)	114	101	0	0	0
Cash at the end of the year	15,133	18,974	18,668	17,023	22,241	28,623
GROWTH	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Revenue	20.2%	20.2%	15.0%	16.3%	20.2%	17.7%
Gross profit	20.3%	18.6%	18.6%	16.9%	20.8%	18.0%
Operating profit	21.6%	21.2%	18.9%	21.9%	20.2%	17.9%
Net profit	20.2%	20.1%	20.5%	22.0%	20.3%	18.0%
Adj. net profit	20.0%	21.3%	20.0%	19.3%	19.0%	17.4%
PROFITABILITY	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Gross profit margin	65.0%	64.2%	66.2%	66.5%	66.9%	67.1%
Operating margin	35.9%	36.2%	37.4%	39.2%	39.2%	39.3%
Adj. net profit margin	31.1%	31.4%	32.7%	33.6%	33.3%	33.2%
Return on equity (ROE)	31.9%	32.6%	35.6%	39.8%	41.7%	42.9%
GEARING/LIQUIDITY/ACTIVITIES	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
Net debt to equity (x)	(0.6)	(0.7)	(0.6)	(0.4)	(0.5)	(0.6)
Current ratio (x)	2.5	2.6	2.7	2.5	3.0	3.6
Receivable turnover days	24.0	26.8	31.1	31.1	31.1	31.1
Inventory turnover days	146.7	127.3	123.6	123.6	123.6	123.6
Payable turnover days	78.0	76.6	76.9	76.9	76.9	76.9
VALUATION	2021A	2022A	2023A	2024E	2025E	2026E
YE 31 Dec						
P/E	38.1	31.6	26.2	22.2	18.6	15.9
Adjusted P/E	38.8	31.9	26.6	22.3	18.7	16.0
P/B	11.3	9.5	9.1	7.9	6.8	5.8
P/CFPS	33.9	25.0	27.5	20.6	17.6	15.0
Div yield (%)	1.4	1.8	2.3	2.9	3.5	4.2

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

Disclosures & Disclaimers

Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings

BUY : Stock with potential return of over 15% over next 12 months
HOLD : Stock with potential return of +15% to -10% over next 12 months
SELL : Stock with potential loss of over 10% over next 12 months
NOT RATED : Stock is not rated by CMBIGM

OUTPERFORM : Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM : Industry expected to underperform the relevant broad market benchmark over next 12 months

CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.